Artificial Oocyte Activation

Ovo Clinic

Status: Active, not recruiting

Conditions: Infertility; Ovarian Insufficiency

Treatments: Other: women having had a second IVF cycle with AOA

Study type: Observational

Funder types: Industry

Identifiers

NCT06290895

3465

Details and patient eligibility

About

Studies reported that calcium signal deficiency or insufficiency during oocyte activation are related with embryo arrest and blastocyst quality. The utilization of Artificial Oocyte Activation (AOA) is safe and does not increase birth defects, cognition, language and motor skills. AOA is the first line of treatment in patients with globozoospermia (round headed spermatozoa). Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists and comprises about 10-15% of patients undergoing controlled ovarian hyperstimulation. The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. The European Society of Human and REproduction (ESHRE) recommends AOA in cases with failed fertilization/ low fertilization.

Enrollment: 54 patients

Sex: Female

Ages: 18 to 42 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with poor or no blastocyst development in their primary cycle
• Group 1 - second cycle using AOA following the poor blastocyst development cycle
• Group 2 - second cycle without AOA following the poor development cycle

Exclusion criteria

• All cycles who do not have repeat cycles following the poor blastocyst development cycle

Trial design

54 participants in 2 patient groups

In-vitro fertilization (IVF) cycle using artificial oocyte activation (AOA)

Treatment:

Other: women having had a second IVF cycle with AOA

In-vitro fertilization (IVF) cycle without artificial oocyte activation (AOA)